Abstract Body

Rapid development of plasma cross-clade neutralization breadth has been described in infants compared to adults. The characteristics of infant HIV-specific antibodies contributing to plasma neutralization breadth have not yet been studied, but may provide unique insights into the process of developing HIV-1-specific broadly neutralizing antibody (bNAb) responses. 

We isolated and characterized neutralizing antibodies (NAb) from an infant sample from 450 days of age (~15 months), an estimated 336 days (~11 months) post-infection – a time when cross-clade NAb breadth was detected in plasma. We used large-scale culture of memory B cells followed by high-throughput neutralization assays to identify HIV-specific B cells. The neutralization breadth of isolated infant-derived NAbs was defined using a diverse panel of envelope variants. The epitope target of the infant-derived antibody demonstrating the greatest neutralization breadth was defined by identifying mutations in known neutralizing epitope targets that confer neutralization resistance.

To date, 9 infant-derived HIV-1-specific neutralizing antibodies have been identified and all are produced from distinct lineages of B cells.  The level of somatic hypermutation (SHM) of infant neutralizing antibodies is significantly lower than adult bNAbs and also NAbs from adults with Tier 1 neutralizing activity but limited cross-clade Tier 2 activity. Several infant NAbs demonstrate heterologous Tier 2 neutralization; one demonstrates cross-clade Tier 2 neutralization breadth against clades A, B and C, and neutralizes 7 of 12 viruses from a standardized panel of global reference viruses.  For this antibody, neutralizing activity is dependent on the N332 residue in V3, a known site of vulnerability and target of adult bNAbs such as PGT121 and PGT128. However, the VH-gene usage of this antibody is not the same as known adult bNAbs that target this site, and SHM is 6.8% at the nucleotide level compared to 17% for PGT121 and 19% for PGT128.

These data suggest that infant responses may be polyclonal and a component of the response includes antibodies targeting a glycan epitope. Furthermore, these data suggest that this infant’s response may target some similar epitopes as adults, but do so using distinct gene families and less SHM.